Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-mir-17-92.

Morelli E, Biamonte L, Federico C, Amodio N, Di Martino MT, Gallo Cantafio ME, Manzoni M, Scionti F, Samur MK, Gullà A, Stamato MA, Pitari MR, Caracciolo D, Sesti S, Frandsen NM, Rossi M, Neri A, Fulciniti M, Munshi NC, Tagliaferri P, Tassone P.

Blood. 2018 Jul 11. pii: blood-2018-03-836601. doi: 10.1182/blood-2018-03-836601. [Epub ahead of print]

PMID:
29997223
2.

Positive Nipple Margin After Nipple-Sparing Mastectomy: An Alternative and Oncologically Safe Approach to Preserving the Nipple-Areolar Complex.

Haslinger ML, Sosin M, Bartholomew AJ, Crocker A, Gulla A, Willey SC, Pittman TA, Tousimis EA.

Ann Surg Oncol. 2018 Aug;25(8):2303-2307. doi: 10.1245/s10434-018-6569-4. Epub 2018 Jun 15.

PMID:
29905891
3.

Timing of radiation therapy in nipple-sparing mastectomy influences outcomes and patient-reported quality of life.

Sosin M, Gulla A, Potdevin L, Cox SE, Bartholomew AJ, Seevaratnam S, Sigdel M, Pittman TA, Willey SC, Tousimis EA.

Breast J. 2018 May 20. doi: 10.1111/tbj.13066. [Epub ahead of print]

PMID:
29781241
4.

Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma.

Samur MK, Minvielle S, Gulla A, Fulciniti M, Cleynen A, Aktas Samur A, Szalat R, Shammas M, Magrangeas F, Tai YT, Auclair D, Keats J, Richardson P, Attal M, Moreau P, Anderson KC, Parmigiani G, Avet-Loiseau H, Munshi NC.

Leukemia. 2018 Mar 29. doi: 10.1038/s41375-018-0116-y. [Epub ahead of print]

PMID:
29749396
5.

How severe is moderately severe acute pancreatitis? Clinical validation of revised 2012 Atlanta Classification.

Ignatavicius P, Gulla A, Cernauskis K, Barauskas G, Dambrauskas Z.

World J Gastroenterol. 2017 Nov 21;23(43):7785-7790. doi: 10.3748/wjg.v23.i43.7785.

6.

Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma.

Gullà A, Hideshima T, Bianchi G, Fulciniti M, Kemal Samur M, Qi J, Tai YT, Harada T, Morelli E, Amodio N, Carrasco R, Tagliaferri P, Munshi NC, Tassone P, Anderson KC.

Leukemia. 2018 Apr;32(4):996-1002. doi: 10.1038/leu.2017.334. Epub 2017 Nov 21.

7.

MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells.

Botta C, Cucè M, Pitari MR, Caracciolo D, Gullà A, Morelli E, Riillo C, Biamonte L, Gallo Cantafio ME, Prabhala R, Mignogna C, Di Vito A, Altomare E, Amodio N, Di Martino MT, Correale P, Rossi M, Giordano A, Munshi NC, Tagliaferri P, Tassone P.

Leukemia. 2018 Apr;32(4):1003-1015. doi: 10.1038/leu.2017.336. Epub 2017 Nov 21.

8.

Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma.

Fulciniti M, Martinez-Lopez J, Senapedis W, Oliva S, Lakshmi Bandi R, Amodio N, Xu Y, Szalat R, Gulla A, Samur MK, Roccaro A, Linares M, Cea M, Baloglu E, Argueta C, Landesman Y, Shacham S, Liu S, Schenone M, Wu SL, Karger B, Prabhala R, Anderson KC, Munshi NC.

Blood. 2017 Apr 20;129(16):2233-2245. doi: 10.1182/blood-2016-06-724831. Epub 2017 Jan 17.

9.

Acute pancreatitis patient registry to examine novel therapies in clinical experience (APPRENTICE): an international, multicenter consortium for the study of acute pancreatitis.

Papachristou GI, Machicado JD, Stevens T, Goenka MK, Ferreira M, Gutierrez SC, Singh VK, Kamal A, Gonzalez-Gonzalez JA, Pelaez-Luna M, Gulla A, Zarnescu NO, Triantafyllou K, Barbu ST, Easler J, Ocampo C, Capurso G, Archibugi L, Cote GA, Lambiase L, Kochhar R, Chua T, Tiwari SC, Nawaz H, Park WG, de-Madaria E, Lee PJ, Wu BU, Greer PJ, Dugum M, Koutroumpakis E, Akshintala V, Gougol A.

Ann Gastroenterol. 2017;30(1):106-113. doi: 10.20524/aog.2016.0109. Epub 2016 Dec 1.

10.

Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma.

Amodio N, Stamato MA, Gullà AM, Morelli E, Romeo E, Raimondi L, Pitari MR, Ferrandino I, Misso G, Caraglia M, Perrotta I, Neri A, Fulciniti M, Rolfo C, Anderson KC, Munshi NC, Tagliaferri P, Tassone P.

Mol Cancer Ther. 2016 Jun;15(6):1364-75. doi: 10.1158/1535-7163.MCT-15-0985. Epub 2016 May 18.

11.

Mir-221/222 are promising targets for innovative anticancer therapy.

Di Martino MT, Rossi M, Caracciolo D, Gullà A, Tagliaferri P, Tassone P.

Expert Opin Ther Targets. 2016 Sep;20(9):1099-108. doi: 10.1517/14728222.2016.1164693. Epub 2016 Mar 21. Review.

PMID:
26959615
12.

A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells.

Gullà A, Di Martino MT, Gallo Cantafio ME, Morelli E, Amodio N, Botta C, Pitari MR, Lio SG, Britti D, Stamato MA, Hideshima T, Munshi NC, Anderson KC, Tagliaferri P, Tassone P.

Clin Cancer Res. 2016 Mar 1;22(5):1222-33. doi: 10.1158/1078-0432.CCR-15-0489. Epub 2015 Nov 2.

13.

Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts.

Pitari MR, Rossi M, Amodio N, Botta C, Morelli E, Federico C, Gullà A, Caracciolo D, Di Martino MT, Arbitrio M, Giordano A, Tagliaferri P, Tassone P.

Oncotarget. 2015 Sep 29;6(29):27343-58. doi: 10.18632/oncotarget.4398.

14.

Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo.

Morelli E, Leone E, Cantafio ME, Di Martino MT, Amodio N, Biamonte L, Gullà A, Foresta U, Pitari MR, Botta C, Rossi M, Neri A, Munshi NC, Anderson KC, Tagliaferri P, Tassone P.

Leukemia. 2015 Nov;29(11):2173-83. doi: 10.1038/leu.2015.124. Epub 2015 May 19.

15.

Myeloid-derived suppressor cells in multiple myeloma: pre-clinical research and translational opportunities.

Botta C, Gullà A, Correale P, Tagliaferri P, Tassone P.

Front Oncol. 2014 Dec 8;4:348. doi: 10.3389/fonc.2014.00348. eCollection 2014. Review.

16.

Mir-34: a new weapon against cancer?

Misso G, Di Martino MT, De Rosa G, Farooqi AA, Lombardi A, Campani V, Zarone MR, Gullà A, Tagliaferri P, Tassone P, Caraglia M.

Mol Ther Nucleic Acids. 2014 Sep 23;3:e194. doi: 10.1038/mtna.2014.47. Review.

17.

Heme oxygenase-1 gene promoter polymorphism is associated with the development of necrotizing acute pancreatitis.

Gulla A, Evans BJ, Navenot JM, Pundzius J, Barauskas G, Gulbinas A, Dambrauskas Z, Arafat H, Wang ZX.

Pancreas. 2014 Nov;43(8):1271-6. doi: 10.1097/MPA.0000000000000171.

PMID:
25036905
18.

Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity.

Raimondi L, Amodio N, Di Martino MT, Altomare E, Leotta M, Caracciolo D, Gullà A, Neri A, Taverna S, D'Aquila P, Alessandro R, Giordano A, Tagliaferri P, Tassone P.

Oncotarget. 2014 May 30;5(10):3039-54.

19.

Transferrin-conjugated SNALPs encapsulating 2'-O-methylated miR-34a for the treatment of multiple myeloma.

Scognamiglio I, Di Martino MT, Campani V, Virgilio A, Galeone A, Gullà A, Gallo Cantafio ME, Misso G, Tagliaferri P, Tassone P, Caraglia M, De Rosa G.

Biomed Res Int. 2014;2014:217365. doi: 10.1155/2014/217365. Epub 2014 Feb 13.

20.

In vivo activity of miR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myeloma.

Di Martino MT, Campani V, Misso G, Gallo Cantafio ME, Gullà A, Foresta U, Guzzi PH, Castellano M, Grimaldi A, Gigantino V, Franco R, Lusa S, Cannataro M, Tagliaferri P, De Rosa G, Tassone P, Caraglia M.

PLoS One. 2014 Feb 27;9(2):e90005. doi: 10.1371/journal.pone.0090005. eCollection 2014.

21.

In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells.

Di Martino MT, Gullà A, Gallo Cantafio ME, Altomare E, Amodio N, Leone E, Morelli E, Lio SG, Caracciolo D, Rossi M, Frandsen NM, Tagliaferri P, Tassone P.

PLoS One. 2014 Feb 21;9(2):e89659. doi: 10.1371/journal.pone.0089659. eCollection 2014.

22.

Emergent pancreaticoduodenectomy: a dual institution experience and review of the literature.

Gulla A, Tan WP, Pucci MJ, Dambrauskas Z, Rosato EL, Kaulback KR, Pundzius J, Barauskas G, Yeo CJ, Lavu H.

J Surg Res. 2014 Jan;186(1):1-6. doi: 10.1016/j.jss.2013.07.057. Epub 2013 Aug 24. Review.

PMID:
24011528
23.

In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma.

Di Martino MT, Gullà A, Cantafio ME, Lionetti M, Leone E, Amodio N, Guzzi PH, Foresta U, Conforti F, Cannataro M, Neri A, Giordano A, Tagliaferri P, Tassone P.

Oncotarget. 2013 Feb;4(2):242-55.

24.

Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth.

Leone E, Morelli E, Di Martino MT, Amodio N, Foresta U, Gullà A, Rossi M, Neri A, Giordano A, Munshi NC, Anderson KC, Tagliaferri P, Tassone P.

Clin Cancer Res. 2013 Apr 15;19(8):2096-106. doi: 10.1158/1078-0432.CCR-12-3325. Epub 2013 Feb 27. Erratum in: Clin Cancer Res. 2014 Oct 15;20(20):5339.

25.

miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1.

Amodio N, Di Martino MT, Foresta U, Leone E, Lionetti M, Leotta M, Gullà AM, Pitari MR, Conforti F, Rossi M, Agosti V, Fulciniti M, Misso G, Morabito F, Ferrarini M, Neri A, Caraglia M, Munshi NC, Anderson KC, Tagliaferri P, Tassone P.

Cell Death Dis. 2012 Nov 29;3:e436. doi: 10.1038/cddis.2012.175.

26.

DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma.

Amodio N, Leotta M, Bellizzi D, Di Martino MT, D'Aquila P, Lionetti M, Fabiani F, Leone E, Gullà AM, Passarino G, Caraglia M, Negrini M, Neri A, Giordano A, Tagliaferri P, Tassone P.

Oncotarget. 2012 Oct;3(10):1246-58.

27.

Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence.

Di Martino MT, Leone E, Amodio N, Foresta U, Lionetti M, Pitari MR, Cantafio ME, Gullà A, Conforti F, Morelli E, Tomaino V, Rossi M, Negrini M, Ferrarini M, Caraglia M, Shammas MA, Munshi NC, Anderson KC, Neri A, Tagliaferri P, Tassone P.

Clin Cancer Res. 2012 Nov 15;18(22):6260-70. doi: 10.1158/1078-0432.CCR-12-1708. Epub 2012 Oct 3.

28.

Promises and challenges of MicroRNA-based treatment of multiple myeloma.

Tagliaferri P, Rossi M, Di Martino MT, Amodio N, Leone E, Gulla A, Neri A, Tassone P.

Curr Cancer Drug Targets. 2012 Sep;12(7):838-46. Review.

Supplemental Content

Support Center